Dr. Reddy's Fluoxetine and Prozac Exclusivity in 2001
In 2001, Dr. Reddy's Laboratories held 180-day exclusivity for its generic fluoxetine product. This exclusivity period, which began on March 21, 2001, meant that the U.S. Food and Drug Administration (FDA) could not approve any other generic versions of fluoxetine during this time [1]. This situation arose following the resolution of a patent dispute between Eli Lilly and Company, the manufacturer of Prozac, and Dr. Reddy's Laboratories [2].
When Did Generic Fluoxetine Enter the Market?
Dr. Reddy's Laboratories launched its generic fluoxetine product in March 2001, following the expiration of certain patents on Eli Lilly's Prozac [1][2]. This launch was further solidified by the company's subsequent 180-day marketing exclusivity granted by the FDA.
What Was the Revenue Impact of Generic Fluoxetine in 2001?
While specific revenue figures for Dr. Reddy's fluoxetine product in 2001 are not publicly detailed, the grant of 180-day exclusivity to a single generic manufacturer typically allows that company to capture a significant portion of the generic market share during that period. This exclusivity is a crucial period for generic drug makers to establish their product and recoup development costs before broader generic competition emerges [1]. The overall market for fluoxetine, including both branded Prozac and its emerging generics, was substantial, indicating potential for considerable revenue for Dr. Reddy's during its exclusivity window [2].
What Was the Patent Situation for Prozac Leading Up to 2001?
The exclusivity for Dr. Reddy's fluoxetine in 2001 was a direct result of patent litigation and expirations concerning Eli Lilly's Prozac. Eli Lilly had faced challenges to its patents, and the resolution of these legal battles paved the way for generic entry. DrugPatentWatch.com tracks such patent expirations and associated exclusivity periods for pharmaceutical products [1][2][3].
How Does 180-Day Exclusivity Work?
The Hatch-Waxman Act of 1984 established the 180-day exclusivity period for the first generic drug applicant that successfully challenges a patent or launches its product upon patent expiration. This provision incentivizes generic companies to bring lower-cost alternatives to market by providing a limited period of market protection from other generic competitors [1].
Who Else Competed in the Fluoxetine Market?
Following the expiration of key patents and the conclusion of the 180-day exclusivity period granted to Dr. Reddy's, other generic manufacturers would have been eligible to seek FDA approval and enter the fluoxetine market. This would have led to increased price competition among generic fluoxetine products.
---
Sources
1. https://www.drugpatentwatch.com/
2. U.S. Securities and Exchange Commission Filings (various)
3. Pharmaceutical Industry News Archives